Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Endocrinology 1, 74–75 (1 December 2005) | doi:10.1038/ncpendmet0052
Is alendronate therapy cost-effective for postmenopausal osteopenia?
Abstract
Schousboe JT et al. (2005) Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Int Med 142: 734–741 Synopsis Background Osteopenia, or low bone mass, is a frequent occurrence in postmenopausal women but is not always associated with osteoporosis or history of fracture.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
